From left to right: Marjan Noor, Sven Bostyn, Fiona Bor

7 December 2016Americas

LSPN 2016: Concerns over pharma becoming ‘big, bad wolf’

The complications surrounding second medical use patents risks the pharmaceutical industry again becoming a “big, bad wolf”.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent

‘We took Ravgen head-on’: How we won zero-damages and others didn't

Bristol Myers Squibb leader named INTA 2025 president

Kathi Vidal to leave USPTO ahead of incoming Trump administration

Herbert Smith Freehills and Kramer Levin in $2bn merger talks